Acyclic Nucleosides as Antiviral Compounds

Applied Biochemistry and Biotechnology - Part B Molecular Biotechnology

Volumn 5, Issue 2, 1996, Pages 125-137

  Freeman, Sally ^a   Gardiner, John M ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

(S) HPMPC; Acyclic nucleoside phosphonates; Acyclic nucleosides; Acyclic oligonucleotides; Acyclovir; Antiviral; Famciclovir; Ganciclovir; HEPT; Penciclovir; PMEA; Purine nucleoside phosphorylase inhibitors; Valaciclovir

Indexed keywords

CUCUMBER MOSAIC VIRUS; HUMAN HERPESVIRUS 3; HUMAN IMMUNODEFICIENCY VIRUS 1;

1 ((2 HYDROXYETHOXY)METHYL) 6 (PHENYLTHIO)THYMINE; 1-((2-HYDROXYETHOXY)METHYL)-6-(PHENYLTHIO)THYMINE; 2 AMINOPURINE; ACICLOVIR; ANTIVIRUS AGENT; DRUG DERIVATIVE; FAMCICLOVIR; GLYCOSYLTRANSFERASE; NUCLEOSIDE; NUCLEOSIDE PHOSPHORYLASE; PRODRUG; THYMINE;

ACYLATION; ANIMAL; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; REVIEW;

2-AMINOPURINE; ACYCLOVIR; ACYLATION; ANIMALS; ANTIVIRAL AGENTS; HIV-1; HUMANS; NUCLEOSIDES; PENTOSYLTRANSFERASES; PRODRUGS; THYMINE;

EID: 0030124517     PISSN: 10736085     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02789061     Document Type: Review

References (94)

1. Bean, B. (1992) Antiviral therapy: current concepts and practices. Clin. Microbiol. Rev. 5, 146-182.
2. van der Sijs, H. and Wiltink, E. H. (1994) Antiviral drugs: present status and future prospects. Int. J. Biochem. 26, 621-630.
3. Kulikowski, T. (1994) Structure-activity relationships and conformational features of antiherpetic pyrimidine and purine nucleoside analogues. A review. Pharm. World Sci. 16, 127-138.
4. Montgomery, J. A. (1993) Purine nucleoside phosphorylase: a target for drug design. Med. Res. Rev. 13, 209-228.
5. Wagstaff, A. J., Faulds, D., and Goa, K. L. (1994) Aciclovir. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic efficacy. Drugs 47, 153-205.
6. Darby, G. (1993) The acyclovir legacy: its contribution to antiviral drug discovery. J. Med. Virol. 1(Suppl.), 134-138.
7. Welsby, P. D. (1994) Acyclovir. Is the honeymoon coming to an end? J. Infect. 28, 121-129.
8. de Ruiter, A. and Thin, R. N. (1994) Genital Herpes. A guide to pharmacological therapy. Drugs 47, 297-304.
9. Wood, M. J. (1994) Current experience with antiviral therapy for acute herpes zoster. Ann. Neurol. 35(Suppl.), S65-S68.
10. Snoeck, R., Andrei, G., and De Clercq, E. (1994) Chemotherapy of varicella zoster virus infections. Int. J. Antimicrob. Agents 4, 211-226.
11. Nikkels, A. F. and Pierard, G. E. (1994) Recognition and treatment of shingles. Drugs 48, 528-548.
12. Ochiai, H., Kumura, K., and Minamishima, Y. (1992) Murine cytomegalovirus DNA polymerase: purification, characterization and role in the antiviral activity of acyclovir. Antiviral Res. 17, 1-16.
13. Talarico, C. L., Phelps, W. C., and Biron, K. K. (1993) Analysis of the thymidine kinase genes from acyclovir-resistant mutants of varicella-zoster virus isolated from patients with AIDS. J. Virol. 67, 1024-1033.
14. de Miranda, P. and Good, S. S. (1992) Species differences in the metabolism and disposition of antiviral nucleoside analogues: 1. Acyclovir. Antiviral Chem. Chemother. 3, 1-8.
15. Domin, B. A., Mahony, W. B., and Zimmerman, T. P. (1991) Desciclovir permeation of the human erythrocyte membrane by nonfacilitated diffusion. Biochem. Pharmacol. 42, 147-152.
16. Purifoy, D. J. M., Beauchamp, L. M., de Miranda, P., Ertl, P., Lacey, S., Roberts, G., Rahim, S. G., Darby, G., Krenitsky, T. A., and Powell, K. L. (1993) Review of research leading to new anti-herpesvirus agents in clinical development: valaciclovir hydrochloride (256U, the L-valyl ester of acyclovir) and 882C, a specific agent for varicella zoster virus. J. Med. Virol. 1(Suppl.), 139-145.
17. Jacobson, M. A. (1993) Valaciclovir (BW256U87): the L-valyl ester of acyclovir. J. Med. Virol. 1(Suppl.), 150-153.
18. Gnann, J. W. (1994) New antivirals with activity against varicella-zoster virus. Ann. Neurol. 35, S69-S72.
19. de Miranda, P. and Burnette, T. C. (1994) Metabolic fate and pharmacokinetics of the acyclovir prodrug valaciclovir in cynomolgus monkeys. Drug Metab. Dispos. 22, 55-59.
20. Burnette, T. C. and de Miranda, P. (1994) Metabolic disposition of the acyclovir prodrug valaciclovir in the rat. Drug Metab. Dispos. 22, 60-64.
21. Weller, S., Blum, M. R., Doucette, M., Burnette, T., Cederberg, D. M., de Miranda, P., and Smiley, M. L. (1993) Pharmacokinetics of the acyclovir pro-drug valaciclovir after escalating single- and multiple-dose administration to normal volunteers. Clin. Pharmacol. Ther. 54, 595-605.
22. Rolan, P. (1995) Pharmacokinetics of new anti-herpetic agents. Clin. Pharmacokin. 29, 333-340.
23. Hosteller, K. Y., Parker, S., Sridhar, C. N., Martin, M. J., Li, J.-L., Stuhmiller, L. M., van Wijk, G. M. T., van den Bosch, H., Gardner, M. F., Aldern, K. A., and Richman, D. D. (1993) Acyclovir diphosphate dimyristoylglycerol: a phospholipid prodrug with activity against acyclovir-resistant herpes simplex virus. Proc. Natl. Acad. Sci. USA 90, 11,835-11,839.
24. Field, A. K., Davies, M. E., DeWitt, C., Perry, H. C., Liou, R., Germershausen, J., Karkas, J. D., Ashton, W. T., Johnston, D. B. R., and Tolman, R. L. (1983) 9-{[2-Hydroxy-1-(hydroxymethyl)ethoxy]methyl} guanine: a selective inhibitor of herpes group virus replication. Proc. Natl. Acad. Sci. USA 80, 4139-4143.
25. Markham, A. and Faulds, D. (1994) Ganciclovir: an update of its therapeutic use in cytomegalovirus infection. Drugs 48, 455-484.
26. Littler, E., Stuart, A. D., and Chee, M. S. (1992) Human cytomegalovirus UL 97 open reading frame encodes a protein that phosphorylates the antiviral nucleoside analogue ganciclovir. Nature 358, 160-162.
27. Stolarski, R., Ciesla, J. M., and Shugar, D. (1990) Monophosphates and cyclic phosphates of some antiviral acyclonucleosides: synthesis, conformation and substrate/inhibitor properties in some enzyme systems. Z. Naturforsch. 45, 293-299.
28. Birnbaum, K. B., Stolarski, R., and Shugar, D. (1994) Structure and conformation of the cyclic phosphate of ganciclovir, a broad-spectrum antiviral agent. Biochim. Biophys. Acta 1200, 55-63 and references therein.
29. Harnden, M. R., Jarvest, R. L., Bacon, T. H., and Boyd, M. R. (1987) Synthesis and antiviral activity of 9-[4-hydroxy-3-(hydroxymethyl)but-1-yl]purines. J. Med. Chem. 30, 1636-1642.
30. Bacon, T. H. and Schinazi, R. F. (1993) An overview of the further evaluation of penciclovir against herpes-simplex virus and varicella-zoster virus in cell-culture highlighting contrasts with acyclovir. Antiviral Chem. Chemother. 4 (Suppl. 1), 25-36.
31. Earnshaw, D. L., Bacon, T. H., Darlison, S. J., Edmonds, K., Perkins, R. M., and Vere Hodge, R. A. (1992) Mode of antiviral action of penciclovir in MRC-5 cells infected with herpes simplex virus type 1 (HSV-1), HSV-2, and varicella-zoster virus. Antimicrob. Agents Chemother. 36, 2747-2757.
32. Weinberg, A., Bate, B. J., Masters, H. B., Schneider, S. A., Clark, J. C., Wren, C. G., Allaman, J. A., and Levin, M. J. (1992) In vitro activities of penciclovir and acyclovir against herpes simplex virus types 1 and 2. Antimicrob. Agents Chemother. 36, 2037,2038.
33. Sutton, D. and Boyd, M. R. (1993) Comparative activity of penciclovir and acyclovir in mice infected intraperitoneally with herpes simplex virus type 1 SC16. Antimicrob. Agents Chemother. 37, 642-645.
34. Shaw, T., Amor, P., Civitico, G., Boyd, M., and Locarnini, S. (1994) In vitro antiviral activity of penciclovir, a novel purine nucleoside, against duck hepatitis B virus. Antimicrob. Agents Chemother. 38, 719-723.
35. Fowles, S. E., Pierce, D. M., Prince, W. T., and Staniforth, D. (1992) The tolerance to and pharmacokinetics of penciclovir (BRL 39123A), a novel antiherpes agent, administered by intravenous infusion to healthy subjects. Eur. J. Clin. Pharmacol. 43, 513-516.
36. Safrin, S. and Phan, L. (1993) In vitro activity of penciclovir against clinical isolates of acyclovir-resistant and foscarnet-resistant herpes simplex virus. Antimicrob. Agents Chemother. 37, 2241-2243.
37. 13C NMR to determine the specificity and absolute configuration of penciclovir phosphate esters formed in HSV-1- and HSV-2-infected cells and by HSV-1-encoded thymidine kinase. Chirality 5, 583-588.
38. Harrell, A. W., Wheeler, S. M., Pennick, M., Clarke, S. E., and Chenery, R. J. (1993) Evidence that famciclovir (BRL 42810) and its associated metabolites do not inhibit the 6 beta-hydroxylation of testosterone in human liver microsomes. Drug Metab. Dispos. Biol. Fate Chem. 21, 18-23.
39. 13C NMR to identify the chiral monoacetylated intermediates in the conversion of famciclovir to penciclovir by human intestinal wall extract. Chirality 5, 577-582.
40. Pue, M. A., Pratt, S. K., Fairless, A. J., Fowles, S., Laroche, J., Georgiou, P., and Prince, W. (1994) Linear pharmacokinetics of penciclovir following administration of single oral doses of famciclovir 125, 250, 500 and 750 mg to healthy volunteers. J. Antimicrob. Chemother. 33, 119-127.
41. Degreef, H., Andrejevic, L., Aoki, F., Arend, J., Ashton, R., De Backer, W., et al. (1994) Famciclovir, a new oral antiherpes drug: Results of the first controlled clinical study demonstrating its efficacy and safety in the treatment of uncomplicated herpes zoster in immunocompetent patients. Int. J. Antimicrob. Agents 4, 241-246.
42. Saltzman, R., Jurewicz, R., and Boon, R. (1994) Safety of famciclovir in patients with herpes zoster and genital herpes. Antimicrob. Agents Chemother. 38, 2454-2457.
43. Balzarini, J. (1994) Metabolism and mechanism of antiretroviral action of purine and pyrimidine derivatives. Pharm. World Sci. 16, 113-126.
44. Kim, C. U., Misco, P. F., Luh, B. Y., and Martin, J. C. (1990) Synthesis of a phosphonate isostere of ganciclovir monophosphate: a highly cytomegalovirus active phosphonate nucleotide analogue. Tetrahedron Lett. 31, 3257-3260.
45. Kim, C. U., Misco, P. F., Luh, B. Y., Hitchcock, M. J. M., Ghazzouli, L, and Martin, J. C. (1991) A new class of acyclic phosphonate nucleotide analogues: phosphonate isosteres of acyclovir and ganciclovir monophosphates as antiviral agents. J. Med. Chem. 34, 2286-2294.
46. Reist, E. J., Sturm, P. A., Pong, R. Y., and Sidwell, R. W. (1989) Synthesis of phosphonic acid analogs of acyclovir (ACV) and ganciclovir (DHPG). Nucleosides Nucleotides 8, 919-922.
47. De Clercq, E., Holy, A., Rosenberg, I., Sakuma, T., Balzarini, J., and Maudgal, P. C. (1986) A novel selective broad-spectrum anti-DNA virus agent. Nature 323, 464-467.
48. De Clercq, E., Holy, A., and Rosenberg, I. (1989) Efficacy of phosphonylmethoxyalkyl derivatives of adenine in experimental herpes simplex virus and vaccinia virus infections in vivo. Antimicrob. Agents Chemother. 33, 185-191.
49. De Clercq, E., Sakuma, T., Baba, M., Pauwels, R., Balzarini, J., Rosenberg, I., and Holy, A. (1987) Antiviral activity of phosphonylmethoxyalkyl derivatives of purine and pyrimidines. Antiviral. Res. 8, 261-272.
50. Terry, B. J., Mazina, K. E., Tuomari, A. V., Haffey, M. L., Hagen, M., Feldman, A., Slusarchyk, W. A., Young, M. G., Zahler, R., and Field, A. K. (1988) Broad-spectrum antiviral activity of the acyclic guanosine phosphonate (R,S)-HPMPG. Antiviral Res. 10, 235-252.
51. Lin, J. C., De Clercq, E., and Pagano, J. S. (1991) Inhibitory effects of acyclic nucleoside phosphonate analogs, including (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine, on Epstein-Barr virus replication. Antimicrob. Agents Chemother. 35, 2440-2443.
52. De Clercq, E. (1993) Therapeutic potential of HPMPC as an antiviral drug. Rev. Med. Virol. 3, 85-96.
53. Snoeck, R., Andrei, G., Gerard, M., Silverman, A., Hedderman, A., Balzarini, J., Sadzot-Delvaux, C., Tricot, G., Clumeck, N., and De Clercq, E. (1994) Successful treatment of progressive mucocutaneous infection due to acyclovir- and foscarnet-resistant herpes simplex virus with (5)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC). Clin. Infect. Dis. 18, 570-578.
54. Snoeck, R., Gerard, M., Sadzot-Delvaux, C., Andrei, G., Balzarini, J., Reymen, D., Ahadi, N., Debruyn, J. M., Piette, J., Rentier, B., Clumeck, N., and De Clercq, E. (1994) Meningoradiculoneuritis due to acyclovir-resistant varicella-zostervirus in an acquired-immunedeficiency-syndrome patients. J. Med. Virol. 42, 338-347.
55. Merta, A., Votruba, I., Jindrich, J., Holy, A., Cihlar, T., Rosenberg, I., Otmar, M., and Herve, T. Y. (1992) Phosphorylation of 9-(2-phosphonomethoxyethyl) adenine and 9-(5)-(3-hydroxy-2-phosphonomethoxypropyl)adenine by AMP(dAMP) kinase from L1210 cells. Biochem. Pharmacol. 44, 2067-2077.
56. Thormar, H., Balzarini, J., Holy, A., Jindrich, J., Rosenberg, I., Debyser, Z., Desmyter, J., and De Clercq, E. (1993) Inhibition of visna virus replication by 2′,3′-dideoxynucleosides and acyclic nucleoside phosphonate analogs. Antimicrob. Agents Chemother. 37, 2540-2544.
57. Balzarini, J., Holy, A., Jindrich, J., Naesens, L., Snoeck, R., Schols, D., and De Clercq, E. (1993) Differential antiherpesvirus and antiretrovirus effects of the (S) and (R) enantiomers of acyclic nucleoside phosphonates: potent and selective in vitro and in vivo antiretrovirus activities of (R)-9-(2-phosphonomethoxypropyl)-2,6-diaminopurine. Antimicrob. Agents Chemother. 37, 332-338.
58. Balzarini, J. and De Clercq, E. (1991) 5-Phosphoribosyl 1-pyrophosphate synthetase converts the acyclic nucleoside phosphonates 9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine and 9-(2-phosphonylmethoxyethyl)adenine directly to their antivirally active diphosphate derivatives. J. Biol. Chem. 266, 8686-8689.
59. Votruba, I., Bernaerts, R., Sakuma, T., De Clercq, E., Merta, A., Rosenberg, I., and Holy, A. (1987) Intracellular phosphorylation of broad-spectrum anti-DNA virus agent (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine and inhibition of viral DNA synthesis. Mol. Pharmacol. 32, 524-529.
60. Merta, A., Votruba, I., Rosenberg, I., Otmar, M., Hrebabecky, H., Bernaerts, R., and Holy, A. (1990) Inhibition of herpes simplex virus DNA polymerase by diphosphates of acyclic phosphonylmethoxyalkyl nucleotide analogues. Antiviral Res. 13, 209-218.
61. Cerny, J., Votruba, I., Vonka, V., Rosenberg, I., Otmar, M., and Holy, A. (1990) Phosphonylmethyl ethers of acyclic nucleoside analogues: inhibitors of HSV-1 induced ribonucleotide reductase. Antiviral Res. 13, 253-264.
62. Yokota, T., Konno, K., Shigeta, S., Holy, A., Balzarini, J., and De Clercq, E. (1994) Inhibitory effects of acyclic nucleoside phosphonate analogs on hepatitis-B virus-DNA synthesis in HB611 cells. Antiviral Chem. Chemother. 5, 57-63.
63. Pauwels, R., Balzarini, J., Schols, D., Baba, M., Desmyter, J., Rosenberg, I., Holy, A., and De Clercq, E. (1988) Phosphonylmethoxyethyl purine derivatives, a new class of anti-human immunodeficiency virus agents. Antimicrob. Agents Chemother. 32, 1025-1030.
64. Balzarini, J., Naesens, L., Herdewijn, P., Rosenberg, I., Holy, A., Pauwels, R., Baba, M., Johns, D. G., and De Clercq, E. (1989) Marked in vivo antiretrovirus activity of 9-(2-phosphonylmethoxyethyl)adenine, a selective anti-human immunodeficiency virus agent. Proc. Natl. Acad. Sci. USA 86, 332-336.
65. Naesens, L., Balzarini, J., and De Clercq, E. (1994) Therapeutic potential of PMEA as an antiviral drug. Rev. Med. Virol. 4, 147-159.
66. Gong, Y.-F., Marshall, D. R., Srinivas, R. V., and Fridland, A. (1994) Susceptibilities of zidovudine-resistant variants of human immunodeficiency virus type 1 to inhibition by acyclic nucleoside phosphonates. Antimicrob. Agents Chemother. 38, 1683-1687.
67. Calio, R., Villani, N., Balestra, E., Sesa, F., Holy, A., Balzarini, J., De Clercq, E., Perno, C. F., and Del Gobbo, V. (1994) Enhancement of natural killer activity and interferon induction by different acyclic nucleoside phosphonates. Antiviral Res. 23, 77-89.
68. Gangemi, J. D., Cozens, R. M., De Clercq, E., Balzarini, J., and Hochkeppel, H.-K. (1989) 9-(2-Phosphonylmethoxyethyl)adenine in the treatment of murine acquired immunodeficiency disease and opportunistic herpes simplex virus infections. Antimicrob. Agents Chemother. 33, 1864-1868.
69. Cihlar, T., Rosenberg, I., Votruba, I., and Holy, A. (1995) Transport of 9-(2-phosphonomethoxyethyl) adenine across plasma-membrane of HeLa S3 cells is protein-mediated. Antimicrob. Agents Chemother. 39, 117-124.
70. Neyts, J. and De Clercq, E. (1994) Mechanism of action of acyclic nucleoside phosphonates against herpes virus replication. Biochem. Pharmacol. 47, 39-41.
71. Balzarini, J., Perno, C.-F., Schols, D., and De Clercq, E. (1991) Activity of acyclic nucleoside phosphonate analogues against human immunodeficiency virus in monocyte/macrophages and peripheral blood lymphocytes. Biochem. Biophys. Res. Commun. 178, 329-335.
72. Balzarini, J., Holy, A., Jindrich, J., Dvorakova, H., Hao, Z., Snoeck, R., Herdewijn, P., Johns, D. G., and De Clercq, E. (1991) 9-[(2RS)-3-Fluoro-2-phosphonylmethoxypropyl] derivatives of purines: a class of highly selective antiretroviral agents in vitro and in vivo. Proc. Natl. Acad. Sci. USA 88, 4961-4965.
73. Heijtink, R. A., Kruining, J., Dewilde, G. A., Balzarini, J., De Clercq, E., and Schalm, S. W. (1994) Inhibitory effects of acyclic nucleoside phosphonates on human hepatitis-B virus and duck hepatitis-B virus-infections in tissue-culture. Antimicrob. Agents Chemother. 38, 2180-2182.
74. Starrett, J. E., Tortolani, D. R., Hitchcock, M. J. M., Martin, J. C., and Mansuri, M. M. (1992) Synthesis and in vitro evaluation of a phosphonate prodrug: bis(pivaloyloxymethyl) 9-(2-phosphonylmethoxyethyl)adenine. Antiviral Res. 19, 267-273.
75. Srinivas, R. V., Robbins, B. L., Connelly, M. C., Gong, Y.-F., Bischofberger, N., and Fridland, A. (1993) Metabolism and in vitro antiretroviral activities of bis(pivaloyloxymethyl) prodrugs of acyclic nucleoside phosphonates. Antimicrob. Agents Chemother. 37, 2247-2250.
76. Srinivas, R. V., Robbins, B. L., Connelly, M. C., Gong, Y.-F., Bischofberger, N., and Fridland, A. (1994) Pivaloyloxymethyl esters of acyclic nucleoside phosphonates. Intl. Antiviral News. 2, 53-55.
77. Uhlmann, E. and Peyman, A. (1990) Antisense oligonucleotides: a new therapeutic principle. Chem. Rev. 90, 543-584.
78. Augustyns, K., Van Aerschot, A., Van Schepdael, A., Urbanke, C., and Herdewijn, P. (1991) Influence of the incorporation of (S)-9-(3,4-dihydroxybutyl)-adenine on the enzymatic stability and base-pairing properties of oligodeoxynucleotides. Nucleic Acids Res. 19, 2587-2593
79. Vandendriessche, F., Augustyns, K. Van Aerschot, A., Busson, R., Hoogmartens, J., and Herdewijn, P. (1993) Acyclic oligonucleotides: possibilities and limitations. Tetrahedron 49, 7223-7238.
80. Egholm, M., Buchardt, O., Nielsen, P. E., and Berg, R. H. (1992) Peptide nucleic acids (PNA). Oligonucleotide analogues with an achiral peptide backbone. J. Am. Chem. Soc. 114, 1895-1897.
81. Buchardt, O., Egholm, M., Berg, R. H., and Nielsen, P. E. (1993) Peptide nucleic acids (PNAs) and their potential applications in biotechnology. Trends Biotechnol. 11, 384-386.
82. Wittung, P., Nielsen, P. E., Buchardt, O., Egholm, M., and Norden, B. (1994) DNA-like double helix formed by peptide nucleic acid. Nature 368, 561-563.
83. Dueholm, K. L., Egholm, M., Behrens, C., Christensen, L., Hansen, H. F., Vulpius, T., Petersen, K. H., Berg, R. H., Nielsen, P. E., and Buchardt, O. (1994) Synthesis of peptide nucleic acid monomers containing the four natural nucleobases: thymine, cytosine, adenine, and guanine and their oligomerization. J. Org. Chem. 59, 5767-5773.
84. Baba, M., Tanaka, H., De Clercq, E., Pauwels, R., Balzarini, J., Schols. D., Nakashima, H., Perno, C.-F., Walker, R. T., and Miyasaka, T. (1989) Highly specific inhibition of human immunodeficiency virus type 1 by a novel 6-substituted acyclouridine derivative. Biochem. Biophys. Res. Commun. 165, 1375-1381.
85. Miyasaka, T., Tanaka, H., Baba, M., Hayakawa, H., Walker, R. T., Balzarini, J., and De Clercq, E. (1989) A novel lead for specific anti-HIV-1 agents: 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine. J. Med. Chem. 32, 2507-2509.
86. Tanaka, H., Baba, M., Saito, S., Miyasaka, T., Takashima, H., Sekiya, K., Ubasawa, M., Nitta, I., Walker, R. T., Nakashima, H., and De Clercq, E. (1991) Specific anti-HIV-1 "acyclonucleosides" which cannot be phosphorylated: synthesis of some deoxy analogues of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine. J. Med. Chem. 34, 1508-1511.
87. Baba, M., De Clercq, E., Tanaka, H., Ubasawa, M., Takashima, H., Sekiya, K., Nitta, I., Umezu, K., Nakashima, H., Mon, S., Shigeta, S., Walker, R. T., and Miyasaka, T. (1991) Potent and selective inhibition of human immunodeficiency virus type 1 (HIV-1) by 5-ethyl-6-phenylthiouracil derivatives through their interaction with the HIV-1 reverse transcriptase. Proc. Natl. Acad. Sci. USA 88, 2356-2360.
88. Boyer, P. L., Currens, M. J., McMahon, J. B., Boyd, M. R., and Hughes, S. H. (1993) Analysis of nonnucleoside drug-resistant variants of human immunodeficiency virus type 1 reverse transcriptase. J. Virol. 67, 2412-2420.
89. Tarrago-Litvak, L., Andreola, M.-L., Nevinsky, G. A., Sarih-Cottin, L., and Litvak, S. (1994) The reverse transcriptase of HIV-1: from enzymology to therapeutic intervention. FASEB J. 8, 497-503.
90. Tuttle, J. V. and Krenitsky, T. A. (1984) Effects of acyclovir and its metabolites on purine nucleoside phosphorylase. J. Biol. Chem. 259, 4065-4069.
91. Bzowska, A., Kulikowska, E., Shugar, D., Bing-Yi, C., Lindborg, B., and Johansson, N. G. (1991) Acyclonucleoside analogue inhibitors of mammalian purine nucleoside phosphorylase. Biochem. Pharmacol. 41, 1791-1803.
92. Ealick, S. E., Babu, Y. S., Bugg, C. E., Erion, M. D., Guida, W. C., Montgomery, J. A., and Secrist, J. A. (1991) III Application of crystallographic and modeling methods in the design of purine nucleoside phosphorylase inhibitors. Proc. Natl. Acad. Sci. USA 88, 11,540-11,544.
93. Kelley, J. L., Linn, J. A., McLean, E. W., and Tuttle, J. V. (1993) 9-[(Phosphonoalkyl)benzyl]guanines. Multisubstrate analogue inhibitors of human erythrocyte purine nucleoside phosphorylase. J. Med. Chem. 36, 3455-3463.
94. Naguib, F. N. M., Levesque, D. L., Wang, E.-C., Panzica, R. P., and el Kouni, M. H. (1993) 5-Benzylbarbituric acid derivatives, potent and specific inhibitors of uridine phosphorylase. Biochem. Pharmacol. 46, 1273-1283.